Harness Therapeutics awarded grant from Michael J. Fox Foundation
The grant funds a two-year proof-of-concept study targeting GCase and LIMP2 upregulation via MISBA platform.
Stay informed with the latest news and media coverage for the biggest companies in Biotechnology & Medical Research. We track all announcements, press releases, and industry mentions in real time, all in one place. Looking for another sector? Browse our industry database.
Last updated
The grant funds a two-year proof-of-concept study targeting GCase and LIMP2 upregulation via MISBA platform.
The study met its safety and tolerability endpoints, with increased drug concentration in blood and cerebrospinal fluid, supporting dose selection for Phase II.
The subscription period ends on June 17, and investors are urged to act today.
The offering aims to raise approximately SEK 30.1 million and is fully secured by major shareholders.
Unlock all announcements with a free trial
STOCKHOLM, SE / ACCESS Newswire / June 16, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting...
Bristol Myers Squibb’s phase 3CheckMate -274 trial of Opdivo in patients with high-risk, muscle-invasive urothelial carcinoma meets primary endpoionts: Princeton, New Jersey Sat ...
Genetic testing company Invitae Corp. has been hit with proposed class privacy claims by an Illinois parent who says the company unlawfully disclosed its patients...
The world's first regulated medical device technology approved to autonomously assess skin cancer from a smartphone will be unveiled today at HLTH Europe.
Unlock all articles with a free trial
Track Every Market Move
Follow your target companies and get daily or weekly news updates delivered straight to your inbox
Start for freeBrowse the top companies in Biotechnology & Medical Research and stay on top of their latest developments.